Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 4:10 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1321–1344 of 21,531 matching trials from the live ClinicalTrials.gov search.
Conditions
Oral Cancer Directed Therapy, Breast Cancer, Gastrointestinal Cancer, Oral Chemotherapy
Interventions
Active Care Team Alert, Passive Care Team Alert
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Neoplasms, Uterine Cervix, Metastatic Cervical Cancer
Interventions
pazopanib (GW786034), lapatinib (GW572016)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Female only
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
12
States / cities
Los Angeles, California • Orange, California • Stanford, California + 9 more
Completed Phase 2 Interventional Results available

The Effect of Sorafenib on Portal Pressure

NCT01714609
Conditions
Clinically Significant Portal Hypertension
Interventions
Placebo, Sorafenib
Drug
Lead sponsor
Yale University
Other
Eligibility
20 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
6
States / cities
New Haven, Connecticut • West Haven, Connecticut • Boston, Massachusetts + 3 more
Completed Not applicable Interventional Accepts healthy volunteers

Mechanisms of Pharyngeal Collapse in Sleep Apnea, Study B

NCT01738009
Conditions
Sleep Apnea
Interventions
Induction of flow limitation
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
21 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Advanced Urothelial Carcinoma
Interventions
copanlisib, Avelumab
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Boston, Massachusetts
Terminated Not applicable Interventional Results available

Endurant Evo US Clinical Trial

NCT02393716
Conditions
Abdominal Aortic Aneurysm, AAA
Interventions
Endurant Evo AAA Stent Graft System, Endovascular aneurysm repair (EVAR)
Device · Procedure
Lead sponsor
Medtronic Cardiovascular
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
14
States / cities
San Diego, California • Stanford, California • Washington D.C., District of Columbia + 11 more
Conditions
Retinal Vein Occlusion, Macula Edema
Interventions
TLC399 (ProDex)
Drug
Lead sponsor
Taiwan Liposome Company
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
20
States / cities
Phoenix, Arizona • Arcadia, California • Beverly Hills, California + 16 more
Conditions
Delirium in Old Age, Delirium, Coronary Artery Disease
Interventions
IV acetaminophen, Placebo
Drug · Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
60 Years and older
Enrollment
901 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
10
States / cities
Birmingham, Alabama • Irvine, California • Los Angeles, California + 5 more
Conditions
Chronic Hepatitis C Virus
Interventions
LDV/SOF, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
647 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
52
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 49 more
Conditions
Hemophilia A
Interventions
SIG-001
Combination Product
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Indianapolis, Indiana • Boston, Massachusetts • Seattle, Washington
Conditions
Phenylketonurias
Interventions
Sapropterin Dihydrochloride, Placebo
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
4 Years to 12 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
9
States / cities
Los Angeles, California • Oakland, California • Sacramento, California + 6 more
Conditions
Metastatic Castration-Resistant Prostate Cancer
Interventions
Onvansertib, Abiraterone, Prednisone
Drug
Lead sponsor
Cardiff Oncology
Industry
Eligibility
18 Years and older · Male only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
3
States / cities
Boston, Massachusetts
Recruiting Not applicable Interventional

MCT for the Harvard/UCSF ROBIN Center

NCT06000787
Conditions
Glioma, Childhood Brainstem, Neuroblastoma
Interventions
External beam radiotherapy, 131I-Metaiodobenzylguanidine (MIBG)
Radiation
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
Not listed
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
San Francisco, California • Boston, Massachusetts
Conditions
Lung Cancer
Interventions
Binimetinib, Palbociclib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Bladder Cancer, Brain and Central Nervous System Tumors, Carcinoma of Unknown Primary, Extragonadal Germ Cell Tumor, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Ovarian Cancer, Sarcoma, Testicular Germ Cell Tumor, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
filgrastim, Amifostine, Carboplatin, Etoposide, Ifosfamide, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
3
States / cities
Boston, Massachusetts
Terminated Phase 4 Interventional Results available

Effects of Atorvastatin on Myonecrosis

NCT00344019
Conditions
Coronary Disease
Interventions
Placebo Oral Tablet, Atorvastatin 80mg, Screening
Drug · Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Systemic Mast Cell Activation, KIT D816V Mutation
Interventions
Screening
Other
Lead sponsor
Blueprint Medicines Corporation
Industry
Eligibility
18 Years and older
Enrollment
379 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
10
States / cities
Birmingham, Alabama • San Diego, California • Boston, Massachusetts + 7 more
Conditions
Coronavirus Infection, Severe Acute Respiratory Infection, Severe Acute Respiratory Syndrome Coronavirus 2
Interventions
Drug: NA-831, NA-831 and Atazanavir, NA-831and Dexamethasone, Atazanavir and Dexamethasone
Drug · Combination Product
Lead sponsor
Biomed Industries, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
525 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
31
States / cities
Los Angeles, California • Orange, California • Palo Alto, California + 27 more
Conditions
Concussion, Mild, Concussion, Brain, TBI (Traumatic Brain Injury), TBI
Interventions
Aerobic Exercise, Balance Exercise
Behavioral
Lead sponsor
Northeastern University
Other
Eligibility
18 Years to 55 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Gastrointestinal Stromal Tumor (GIST)
Interventions
DCC-3009, Rabeprazole
Drug
Lead sponsor
Deciphera Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
10
States / cities
Scottsdate, Arizona • La Jolla, California • Aurora, Colorado + 7 more
Conditions
Bronchopulmonary Dysplasia
Interventions
Furosemide Cohort 1, Furosemide Cohort 2, Furosemide Cohort 3, Placebo
Drug · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
7 Days to 28 Days
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
21
States / cities
Little Rock, Arkansas • Loma Linda, California • Jacksonville, Florida + 17 more
Conditions
Atrial Fibrillation, Ischemic Stroke
Interventions
Atrial fibrillation risk electronic health record alert
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
805 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 2 Interventional Results available

Eribulin in HER2 Negative Metastatic BrCa

NCT01827787
Conditions
Breast Cancer
Interventions
Eribulin
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
7
States / cities
Bangor, Maine • Boston, Massachusetts • Milford, Massachusetts + 2 more
Conditions
Melanoma, Advanced Melanoma, Metastatic Melanoma, Unresectable Melanoma
Interventions
CMP-001, Nivolumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
25
States / cities
Phoenix, Arizona • Duarte, California • Los Angeles, California + 21 more